Table 1 Patient demographics, disease characteristics, and prior treatment regimens
Characteristic | Number of patients |
|---|---|
(N = 133) | |
Sex, n (%) | |
Male | 70 (52.6) |
Female | 63 (47.4) |
Age, years | |
Median (range) | 59.4 (16–83) |
Comorbidities, n (%) | |
Hypertension | 51 (38.3) |
Diabetes | 37 (27.8) |
Dyslipidaemia | 25 (18.8) |
Heart disease | 19 (14.3) |
Liver disease | 6 (4.5) |
Hypothyroidism | 12 (9.0) |
Tumour extension at diagnosis, n (%) | |
Locally advanced | 6 (4.5) |
Metastatic | 127 (95.5) |
Tumour extension at treatment initiation, n (%) | |
Locally advanced | 2 (1.5) |
Metastatic | 131 (98.5) |
ECOG PS, n (%) | |
0 | 45 (33.8) |
1 | 65 (48.9) |
2 | 22 (16.5) |
3 | 1 (0.8) |
Location of primary tumour, n (%) | |
Foregut | 85 (64.0) |
Lung | 12 (9.0) |
Oesophagus | 1 (0.8) |
Stomach | 3 (2.3) |
Duodenum | 5 (3.8) |
Pancreas | 64 (48.1) |
Midgut | 30 (22.6) |
Jejunum | 3 (2.3) |
Ileum | 21 (15.8) |
Appendix | 2 (1.5) |
Cecum | 4 (3.0) |
Hindgut | 6 (4.5) |
Colon | 3 (2.3) |
Rectum | 3 (2.3) |
Unknown | 12 (9.0) |
Histological differentiation, n (%) | |
Grade 1 | 55 (41.4) |
Grade 2 | 42 (31.6) |
Grade 3 | 2 (1.5) |
Unknown | 34 (25.6) |
Location of metastases, n (%) | |
Liver | 112 (84.2) |
Bone | 18 (13.5) |
Peritoneum | 19 (14.3) |
Lung | 19 (14.3) |
Lymph node | 29 (21.8) |
Othera | 4 (3.0) |
Tumour functionality, n (%) | |
Non-functioning | 92 (69.2) |
Functioning | 41 (30.8) |
Carcinoid | 13 (9.8) |
Gastrinoma | 1 (0.8) |
Somatostinoma | 1 (0.8) |
VIPoma | 3 (2.3) |
Not specified | 23 (17.3) |
Ki-67 index, n (%) | |
0–2 | 52 (39.1) |
3–10 | 29 (21.8) |
11–20 | 8 (6.0) |
> 20 | 1 (0.8) |
Unknown | 43 (32.3) |
Previous non-pharmacologic treatments, n (%) | |
Surgery of the primary tumour | 63 (47.4 %) |
Surgery of metastases | 21 (15.8 %) |
Local treatmentsb | 23 (17.3) |
Radiotherapy | 6 (4.5) |
Previous pharmacologic treatments, n (%) | |
None | 16 (12.0) |
Chemotherapy | 45 (33.8) |
Targeted therapy | 16 (12.0) |
Immunotherapy | 7 (5.3) |
Somatostatin analogues | |
Lanreotide | 78 (58.6) |
Octreotide | 37 (27.8) |
Combination with somatostatin analogues | |
Interferon | 19 (14.3) |
Targeted therapy | 7 (5.3) |